Find your care
Radiation oncologists use a patient-centered approach and individualized treatment plans. To learn more and make an appointment with a UCLA radiation oncologist, contact us at:
Stereotactic Body Radiotherapy for Liver Metastases and Hepatocellular Carcinoma Utilizing an MRI-Guided Tri-60 Teletherapy System
Clinical Trial: Liver Cancer
Testing the Feasibility of a Unique Radiation Therapy Machine Which is Guided by MRI for People with Liver Cancer
Standard treatment for tumors of the liver includes stereotactic body radiotherapy (SBRT). While SBRT is effective, very often an extra amount of radiation must be added to ensure the SBRT treatment is reaching the location of the tumor.
Combining MRI with radiation therapy may enable us to highlight the tissues surrounding the tumor better, which can help us see soft tissue and visualize and adjust the radiation dose, without invasive procedures or exposing patients to additional radiation, which is common with other radiation treatment types. We hope to eliminate the number of normal tissues exposed to radiation and increase tumor control through this system.
This study does not replace any of the routine radiation treatment patients would typically receive at UCLA. Instead, the purpose of this research study is to determine if the new MRI-guided system can be used to develop optimal treatment plans for liver SBRT.
All treatment in this study is considered standard of care, and uses an FDA-approved device, the Viewray system™.
Subjects will undergo routine radiation therapy planning which includes either MRI, CT scans or a combination of both.
Standard, routine radiation will be delivered in five separate doses, requiring five separate visits to UCLA Department of Radiation Oncology. Patients will return to UCLA for routine follow-up visits after the completion of radiation therapy, which take place about once every three months for the first year.
Eligibility Criteria (Basic):
- Must be 18 years of age or older
- Must have cancer present in the liver either due to metastases or due to primary liver cancer
Other eligibility criteria exist.
For More Detailed Information Contact: